## CL: Colgate-Palmolive Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 -1.6% below STRENGTH zone (3.0-6.0%); PEG 1.60 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.82)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. RBC Capital upgrades Colgate-Palmolive stock to Outperform on favorable setup**
- Source: Investing.com UK | 20251209T090827 | Bullish | Relevance: 99%
- RBC Capital has upgraded Colgate-Palmolive Company (NYSE:CL) from Sector Perform to Outperform, maintaining an $88.00 price target. This decision comes despite recent stock pressure due to slowing global category growth, as RBC Capital believes current expectations are appropriately lowered and the risk-reward profile is favorable. The company recently reported increased net sales and EPS for Q2 2025, affirming its commitment to low single-digit EPS growth for the year.

**2. RBC Capital Upgrades Colgate-Palmolive Company (CL) to Outperform**
- Source: StreetInsider | 20251209T075736 | Bullish | Relevance: 99%
-  RBC Capital analyst Nik Modi has upgraded Colgate-Palmolive Company (NYSE: CL) from Sector Perform to Outperform. The firm also assigned a new price target for the stock. Further details are available to premium subscribers.

**3. Axa S.A. Has $101.36 Million Holdings in Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251209T083503 | Somewhat-Bullish | Relevance: 99%
-  Axa S.A. significantly increased its stake in Colgate-Palmolive Company, purchasing an additional 333,001 shares in the 2nd quarter, bringing its total holdings to over 1.1 million shares valued at $101.36 million. This move represents a 42.6% rise in their investment, making Axa S.A. a prominent institutional holder of Colgate-Palmolive stock. Other institutional investors also adjusted their positions, while Wall Street analysts offered a "Moderate Buy" consensus despite varied price targets.

**4. Ossiam Boosts Position in Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251208T115104 | Somewhat-Bullish | Relevance: 99%
- Ossiam significantly increased its stake in Colgate-Palmolive Company (NYSE:CL) by 1,874.7% in Q2, bringing its total holdings to 318,692 shares valued at approximately $28.97 million. Other major institutional investors like Vanguard, T. Rowe Associates, Norges Bank, Invesco, and Ameriprise Financial also increased their positions, resulting in institutional investors owning about 80.41% of the stock. Colgate-Palmolive reported stronger-than-expected quarterly EPS of $0.91 and a $0.52 quarterly dividend, and holds a consensus analyst rating of "Moderate Buy" with a target price of $89.87.

**5. Federated Hermes Inc. Has $42.44 Million Stake in Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251209T100812 | Neutral | Relevance: 99%
-  Federated Hermes Inc. decreased its stake in Colgate-Palmolive Company (NYSE:CL) by 22.2% during the second quarter, still holding 466,895 shares worth $42.44 million. Other institutional investors have adjusted their holdings, with 80.41% of the company's stock owned by institutional investors and hedge funds. Analyst ratings for Colgate-Palmolive currently lean towards a "Moderate Buy" with an average price target of $89.87.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | RBC Capital | $88 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | RBC Capital | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.07M) |
| Sells | 23 ($1.66M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.2%)
- Blackrock Inc.: 8.6% (+0.5%)
- State Street Corpora: 6.0% (+0.2%)
- Price (T.Rowe) Assoc: 4.0% (-11.5%)
- Geode Capital Manage: 2.7% (+4.1%)

### Key Risks

1. Long-term trend broken: trading 9.8% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.60 elevated, pricing in significant growth expectations. Forward P/E 20.2x stretched relative to 5% growth. Quality metrics strong (ROE 294%, ROA 15%). Balance sheet: $1.1B free cash flow. Insider selling cluster ($1.7M in 90 days), potential headwind. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $62.8B |
| Beta | 0.29 |
| 52W Range | $74.55 - $100.18 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.60 |
| Forward P/E | 20.2 |
| Current P/E | 21.3 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.2% to -1.6% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.6pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.2%) - potential reversal signal. Below SMA200 (0.90x), long-term trend not supportive. RSI neutral at 47.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.64% (CS: 32) | Neutral |
| RSI_14 | 46.9 | Neutral |
| MACD Histogram | -0.26 | Bearish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 0.994x | Below |
| vs SMA200 | 0.902x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $77.76
- **Stop Loss:** $74.82 (3.8% risk)
- **Target:** $80.70 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 170
- **Position Value:** $13,219.20
- **Portfolio %:** 13.22%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-01-30 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.89 | $0.91 | +2.4% |
| 2025Q2 | $0.89 | $0.92 | +2.8% |
| 2025Q1 | $0.86 | $0.91 | +6.1% |
| 2024Q4 | $0.89 | $0.91 | +2.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*